Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 9OTHER 2NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Rectal Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Drug-Related Side Effects and Adverse Reactions 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 50Paclitaxel 48Cisplatin 39Gemcitabine 31Erlotinib Hydrochloride 30Radiotherapy 28Docetaxel 24Taxes 21Specimen Handling 20Magnetic Resonance Spectroscopy 20Vinorelbine 16Pemetrexed 12Etoposide 12Bevacizumab 12Radiation 10Gefitinib 10aldesleukin 8Platinum 8Bortezomib 8Biopsy 8Vinblastine 7Azacitidine 71,2-diaminocyclohexaneplatinum II citrate 7pembrolizumab 6atezolizumab 6Observation 6Immunoglobulin G 6Disulfides 6Cyclophosphamide 6Chemotherapy, Adjuvant 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Carcinoma, Non-Small-Cell Lung × Folic Acid × Clear all
NCT00923273 2019-11-26

Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
42 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00033722 2014-01-06

Lometrexol Plus Folic Acid in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡